<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322786</url>
  </required_header>
  <id_info>
    <org_study_id>ISAC17_205R</org_study_id>
    <nct_id>NCT04322786</nct_id>
  </id_info>
  <brief_title>The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?</brief_title>
  <official_title>The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study use UK based linked electronic health records from the Clinical Research Datalink
      (CALIBER) of 5.6 million individuals to conduct a matched case-control study to investigate
      the incidence of influenza in individuals prescribed ACEI compared to those not prescribed
      ACEI.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 1998</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of influenza</measure>
    <time_frame>Jan 1st 1998 - May 31st 2016</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1302508</enrollment>
  <condition>Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom</condition>
  <arm_group>
    <arm_group_label>ACEI user</arm_group_label>
    <description>Individuals with an ACEI prescription in the study population.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched controls</arm_group_label>
    <description>Individuals without an ACEI prescription, and matched to the users by sex and 10-year age categories.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor</intervention_name>
    <description>Any prescription of ACE inhibitor</description>
    <arm_group_label>ACEI user</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The nested case-control study include cases who had an ACEI prescription during study
        follow-up. We randomly select one control per case from the study cohort of individuals
        without any documented ACEI use. Controls are matched to incident AF patients according to
        sex, age (10-year age strata).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  We identify individuals aged 18 years or older and registered in the current primary
             care practice for at least one year.

        Exclusion Criteria:

          -  We exclude individuals with a prior history of influenza and viral pneumonia before
             study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

